298 patents
Page 11 of 15
Utility
PYRROLO[2,3-D]PYRIMIDINONE Compounds As CDK2 Inhibitors
16 Dec 20
The present application provides pyrrolo[2,3-d]pyrimidinone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao
Filed: 13 Feb 20
Utility
TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
9 Dec 20
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
Filed: 25 Jun 20
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
9 Dec 20
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 9 Jun 20
Utility
Substituted Tricyclic Compounds As FGFR Inhibitors
2 Dec 20
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liangxing Wu, Colin Zhang, Chunhong He, Yaping Sun, Liang Lu, Ding-Quan Qian, Meizhong Xu, Jincong Zhuo, Wenqing Yao
Filed: 6 Apr 20
Utility
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
2 Dec 20
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 13 Aug 20
Utility
Topical Formulation for a Jak Inhibitor
25 Nov 20
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish PARIKH, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 13 Aug 20
Utility
Tricyclic Amine Compounds As CDK2 Inhibitors
4 Nov 20
The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Ken Mukai, Liangxing Wu, Wenqing Yao
Filed: 29 Apr 20
Utility
Tricyclic Amine Compounds As CDK2 Inhibitors
4 Nov 20
The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Neil Lajkiewicz, Ken Mukai, Liangxing Wu, Wenqing Yao
Filed: 29 Apr 20
Utility
Salts of Tam Inhibitors
4 Nov 20
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li
Filed: 18 Mar 20
Utility
Biomarkers for Vitiligo
4 Nov 20
Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
Filed: 17 Mar 20
Utility
HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
28 Oct 20
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 16 Mar 20
Utility
AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
28 Oct 20
Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
Filed: 13 Apr 20
Utility
3-(5-AMINO-PYRAZIN-2-YL)-BENZENESULFONAMIDE Derivatives and Related Compounds As PI3K-GAMMA Kinase Inhibitors for Treating E.g. Cancer
21 Oct 20
Artem SHVARTSBART, Andrew P. COMBS, Nikoo FALAHATPISHEH, Padmaja POLAM, Lixin SHAO, Stacey SHEPARD
Filed: 19 Dec 18
Utility
Heterocyclylamines As PI3K Inhibitors
14 Oct 20
Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
Filed: 23 Mar 20
Utility
Heterocyclic Compounds As Immunomodulators
14 Oct 20
Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
Filed: 25 Jun 20
Utility
Formulations of an LSD1 Inhibitor
7 Oct 20
The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.
William L. Rocco, Ying Liu, Mei Li, Tanvi Shah, Huifang Wu
Filed: 21 Jun 20
Utility
Cyclin-dependent Kinase 2 Biomarkers and Uses Thereof
7 Oct 20
Biomarkers are provided that are predictive and/or indicative of a subject's responsiveness to a cyclin-dependent kinase 2 (CDK2) inhibitor.
Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo, Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao
Filed: 13 Feb 20
Utility
Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
7 Oct 20
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
Filed: 22 Jun 20
Utility
Bicyclic Heterocycles As FGFR4 Inhibitors
30 Sep 20
The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
Filed: 11 Mar 20
Utility
Methods of Treating Cancer with an FGFR Inhibitor
9 Sep 20
This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
Tao Ji, Krishnaswamy Yeleswaram
Filed: 5 Mar 20